Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772801 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7835291 | 0.86 | SLC6A2 (0.62) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7996118 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2211203 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2208714 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5306302 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5659467 | 0.83 | SLC6A4 (0.49) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6696040 | 0.83 | SLC6A4 (0.49) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7306045 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9293360 | 0.81 | SLC6A9 (0.53) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4313896-A | ANTIDEPRESSANTS, PSYCHOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | SLC6A2 374/4885SLC6A4 340/4885CYP1A2 309/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | SLC6A2 550/4885SLC6A4 596/4885CYP1A2 316/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | SLC6A2 290/4885SLC6A4 280/4885CYP1A2 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.